{"id":3227,"date":"2023-05-24T22:41:05","date_gmt":"2023-05-24T20:41:05","guid":{"rendered":"https:\/\/jacked.sk\/obchod\/cjc-1295-dac\/"},"modified":"2026-08-21T14:28:10","modified_gmt":"2026-08-21T12:28:10","slug":"cjc-1295-dac-2mg","status":"publish","type":"product","link":"https:\/\/dev.jacked.sk\/en\/research-on-muscle-growth\/cjc-1295-dac-2mg\/","title":{"rendered":"CJC-1295 + DAC 2 mg"},"content":{"rendered":"
\n\n\t
\n\t\t\t\t
\n\t\t\t\n\t\t\t\n

CJC-1295 + DAC 2 mg \u2013 Long-Acting GHRH Analog (Research)<\/h1>\n

\u26a0\ufe0f Warning:<\/strong> CJC-1295 + DAC is intended exclusively for scientific and research purposes. It is not intended for human use as a medication, dietary supplement, or cosmetic product. Sale restricted to individuals 18 years of age or older.
\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\n\t\n\n\t

\n\t\t\t\t
\n\t\t\t\n\t\t\t\n

What is CJC-1295 + DAC?<\/h2>\n

CJC-1295 + DAC is a synthetic analog of GHRH (Growth Hormone-Releasing Hormone)<\/strong> \u2014a hormone that stimulates the pituitary gland in the human body to release growth hormone (GH). The abbreviation DAC stands for Drug Affinity Complex<\/strong> \u2014a chemical modification that radically alters the pharmacokinetic profile of this molecule.
\nStructurally, it is a modified fragment of GHRH(1-29) with four amino acid substitutions (Ala\u2192Aib, Arg\u2192Lys, Gln\u2192Ala, Cys34\u2192Cys34) and an added maleimido-propionic acid (DAC) group at the C-terminus of the molecule. The molecular weight of CJC-1295 + DAC is 3,647 Da<\/strong>, which classifies it as a medium-sized peptide.
\nCJC-1295 + DAC is the subject of research primarily in the areas of growth hormone physiology, muscle tissue metabolism, and body composition. In preclinical protocols, it is used because of its significantly prolonged biological half-life compared to native GHRH or uncomplexed analogs.
\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\n\t\n\n\t

\n\t\t\t\t
\n\t\t\t\n\t\t\t\n

The role of the DAC group: prolonging the biological half-life<\/h2>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\n\t\n\n\t
\n\t\t\t\t
\n\t\t\t\n\t\t\t\n

Mechanism of binding to albumin<\/h3>\n

A key property of CJC-1295 + DAC is its ability to covalently bind to serum albumin<\/strong> in the bloodstream. This is facilitated by the DAC group (maleimido-propionic acid) at the C-terminus of the peptide, which reacts with the thiol groups of cysteine in the albumin molecule.
\nAlbumin is the most abundant plasma protein (40\u201350 g\/L in human blood), with a natural role as a carrier of hydrophobic molecules and a long biological half-life (approximately 19 days). By binding to albumin, CJC-1295 + DAC assumes its kinetic properties, thereby avoiding rapid degradation by endopeptidases and renal filtration.
\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\n\t\n\n\t

\n\t\t\t\t
\n\t\t\t\n\t\t\t\n

Comparison of half-lives: native GHRH vs. CJC-1295 without DAC vs. CJC-1295 + DAC<\/h3>\n

Research data document a significant difference in the biological half-life among the various forms of GHRH analogs:<\/p>\n\n\n\n\n\n\n
Compound<\/strong><\/td>\nBiological half-life<\/strong><\/td>\nGH secretion profile<\/strong><\/td>\n<\/tr>\n
Native GHRH<\/td>\n~7\u201310 minutes<\/td>\nPulsatile, short-acting<\/td>\n<\/tr>\n
Modified GRF 1-29 (CJC without DAC)<\/td>\n~30 minutes<\/td>\nPulsatile, medium-length<\/td>\n<\/tr>\n
CJC-1295 + DAC<\/strong><\/td>\n6\u20138 days<\/strong><\/td>\nStable, long-term<\/strong><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

This difference is crucial from a research perspective: while uncomplexed analogs simulate the physiological pulsatile secretion of GH, CJC-1295 + DAC maintains continuously elevated levels of GH and IGF-1 for several days.
\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\n\t\n\n\t

\n\t\t\t\t
\n\t\t\t\n\t\t\t\n

Mechanism of Action in Research<\/h2>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\n\t\n\n\t
\n\t\t\t\t
\n\t\t\t\n\t\t\t\n

Activation of GHRH receptors in the pituitary gland<\/h3>\n

CJC-1295 + DAC acts as a GHRH receptor (GHRHR) agonist<\/strong> on somatotrophic cells in the anterior lobe of the pituitary gland. By binding to GHRHR, it activates a signaling cascade via adenylate cyclase \u2192 increased intracellular cAMP concentration \u2192 PKA activation \u2192 expression and secretion of growth hormone (GH).
\nDue to the prolonged half-life of the DAC group, this axis undergoes long-term, non-pulsatile<\/strong> activation, which represents a distinct research model compared to other GHRH analogs.
\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\n\t\n\n\t

\n\t\t\t\t
\n\t\t\t\n\t\t\t\n

Growth hormone secretion and IGF-1 production<\/h3>\n

Increased secretion of GH from the pituitary gland stimulates the liver to produce IGF-1 (Insulin-like Growth Factor 1)<\/strong> \u2014a mediator through which GH exerts most of its anabolic and lipolytic effects in peripheral tissues.
\nIn preclinical studies, rats administered CJC-1295 + DAC showed an increase in serum GH and IGF-1 levels that persisted throughout the observation period (5\u201312 days), confirming the compound\u2019s long-term activity.
\nSource: Teichman SL et al., Journal of Clinical Endocrinology & Metabolism (2006)<\/em>
\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\n\t\n\n\t

\n\t\t\t\t
\n\t\t\t\n\t\t\t\n

Preclinical results: muscle mass and adipose tissue<\/h3>\n

In studies using animal models with chronic administration of CJC-1295 + DAC, researchers observed:- An increase in<\/strong> lean body mass<\/strong> compared to control groups – A reduction in the percentage of adipose tissue<\/strong> (both visceral and subcutaneous fat) with long-term administration – An increase in bone density in some protocols (preliminary data)
\nThese results form the basis for further scientific research on the GH-GHRH axis in the context of body composition metabolism.
\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\n\t\n\n\t

\n\t\t\t\t
\n\t\t\t\n\t\t\t\n

Comparison: CJC-1295 + DAC vs. Modified GRF 1-29<\/h2>\n\n\n\n\n\n\n\n\n\n
Property<\/strong><\/td>\nCJC-1295 + DAC<\/strong><\/td>\nModified GRF 1-29 (CJC without DAC)<\/strong><\/td>\n<\/tr>\n
Biological half-life<\/td>\n6\u20138 days<\/td>\n~30 minutes<\/td>\n<\/tr>\n
DAC Group<\/td>\nYES (albumin-binding)<\/td>\nNO<\/td>\n<\/tr>\n
GH Secretion Profile<\/td>\nStable, continuous<\/td>\nPulsatile<\/td>\n<\/tr>\n
Frequency Protocol (Research)<\/td>\nOnce a week<\/td>\n1\u20132 times a day<\/td>\n<\/tr>\n
MW<\/td>\n3,647 Da<\/td>\n3,370 Da<\/td>\n<\/tr>\n
Research Application<\/td>\nLong-term studies of GH levels<\/td>\nSimulation of physiological pulsatility<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

The choice between CJC-1295 + DAC and Modified GRF 1-29 depends on the objectives of the research protocol. For studies requiring a stable, long-term elevation of GH\/IGF-1, CJC-1295 + DAC is the standard choice.
\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\n\t\n\n\t

\n\t\t\t\t
\n\t\t\t\n\t\t\t\n

Technical Specifications<\/h2>\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n
Parameter<\/strong><\/td>\nValue<\/strong><\/td>\n<\/tr>\n
Chemical Name<\/strong><\/td>\nCJC-1295 + DAC (CJC-1295 with Drug Affinity Complex)<\/td>\n<\/tr>\n
Form<\/strong><\/td>\nGHRH analog with a C-terminal DAC group<\/td>\n<\/tr>\n
Molecular weight<\/strong><\/td>\n3,647 Da<\/td>\n<\/tr>\n
Contents per package<\/strong><\/td>\n2 mg<\/td>\n<\/tr>\n
Purity<\/strong><\/td>\n\u2265 98% (HPLC-verified)<\/td>\n<\/tr>\n
Product Form<\/strong><\/td>\nFreeze-dried white powder<\/td>\n<\/tr>\n
CAS Number<\/strong><\/td>\n863288-34-0<\/td>\n<\/tr>\n
Biological half-life<\/strong><\/td>\n6\u20138 days (after binding to albumin)<\/td>\n<\/tr>\n
Recommended storage conditions<\/strong><\/td>\n\u221220 \u00b0C, protected from light and moisture<\/td>\n<\/tr>\n
Stability (lyophilisate)<\/strong><\/td>\nUp to 24 months at \u221220 \u00b0C<\/td>\n<\/tr>\n
Stability (reconstituted)<\/strong><\/td>\nUp to 14 days at 4 \u00b0C, up to 3 months at \u221220 \u00b0C<\/td>\n<\/tr>\n
Intended Use<\/strong><\/td>\nFor scientific research purposes only<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\n\t\n\n\t
\n\t\t\t\t
\n\t\t\t\n\t\t\t\n

Frequently Asked Questions About CJC-1295 + DAC<\/h2>\n
\n\t
\n\t\t\n\t\t\t